SUNNYVALE, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ:BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the third quarter of 2026 by conference call on Thursday, November 12, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.
Participants can register for the conference by navigating to: https://dpregister.com/sreg/10213286/10535c5b644
Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=O8EiucRo
A webcast replay of the call will be available approximately one hour after the end of the call through approximately November 12, 2026 at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada), 1-412-317-0088 (international toll) by using access code 8587782.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company's biotherapeutic platforms, with three cardiac clinical-stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms, and its Heart3D™ fusion imaging platform under development. For more information visit www.biocardia.com.
MEDIA CONTACT:
Miranda Peto, Investor Relations
mpeto@biocardia.com
(650) 226-0120
INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120
